Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GDC-0425

Known as: Chk1 Inhibitor GDC-0425 
An orally bioavailable inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Purpose: Chk1 inhibition potentiates DNA-damaging chemotherapy by overriding cell-cycle arrest and genome repair. This phase I… Expand
Is this relevant?
2017
2017
GDC-0425 [5-((1-ethylpiperidin-4-yl)oxy)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile] is an orally bioavailable small… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of GDC-0425 concentrations in human… Expand
Is this relevant?
2015
2015
The development and validation of a method for the determination of concentrations of thiocya nate in human plasma are described… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2015
2015
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Background: Checkpoint kinase 1 (Chk1) acts at… Expand
Is this relevant?
2015
2015
GDC-0425 is a potent and selective small molecule inhibitor of checkpoint kinase 1 (Chk1) recently evaluated in the DPM4957g… Expand
Is this relevant?